Page 20 - RxExam's Naplex Theory Book Part 2

www.pharmacyexam.com Krisman

Miscellaneous:
Dose Special Notes

Colchicine 1. Gout, prophylaxis: 1). Colchicine (Colcrys) disrupts cytoskeletal functions through
(Tablet) inhibition of β-tubulin polymerization into microtubules, and
0.5 to 0.6 mg PO consequently prevents the activation, degranulation, and migration of
once a day. neutrophils thought to mediate some gout symptoms. It is indicated
for the following:
2. Gout, treatment:
a). Treatment and prophylaxis of gout flares
1.2 mg PO at the b). Familial Mediterranean Fever (FMF) in adults and children 4 years
first sign of flare or older
followed by 0.6
mg I hour later. 2). Co-administration of Colchicine (Colcrys) with drugs known to
Do not exceed 1.8 inhibit CYP3A4 and/or P-glycoprotein (P-gp) increases the risk of
mg within 1 hour. colchicine-induced toxic effects. If patients are taking or have recently
completed treatment with such drugs within the prior 14 days, the
3. FMF: dose adjustments of Colchicine (Colcrys) are required.

1.2 to 2.4 mg per 3). The most commonly reported adverse reaction in clinical trials of
day given in 1 or 2 colchicine for the prophylaxis of gout was diarrhea. Nausea, vomiting,
divided doses. abdominal discomfort, headache and fatigue are also reported with
the therapy.

Terminology

Familial Familial Mediterranean Fever (FMF) is also called recurrent
Mediterranean polyserositis. The salient features of FMF include brief recurrent
Fever (FMF) episodes of peritonitis, pleuritis, and arthritis, usually with
accompanying fever. FMF occurs within families and is much more
common in individuals of Mediterranean descent than in persons of
any other ethnicity.

19